Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws

@article{Woo2006SystematicRB,
  title={Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws},
  author={Sook-Bin Woo and John W Hellstein and John R. Kalmar},
  journal={Annals of Internal Medicine},
  year={2006},
  volume={144},
  pages={753-761}
}
Key Summary Points Osteonecrosis of the jaws is strongly associated with the use of aminobisphosphonates, and the mechanism of disease is probably severe suppression of bone turnover. Ninety-four percent of patients are treated with zoledronic acid or pamidronate or both; 85% of affected patients have multiple myeloma or metastatic breast cancer, and 4% have osteoporosis. The prevalence of osteonecrosis in patients with cancer is 6% to 10% and the prevalence in those taking alendronate for… Expand
Osteonecrosis of the jaw.
TLDR
Osteonecrosis of the jaw (ONJ) is a newly described condition (2003) defined as exposed bone in the maxillofacial area, not associated with radiation or any other known cause and not healing for 8 weeks, and it does occur in patients receiving oral or i.v. bisphosphonate therapy for cancer. Expand
Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases
TLDR
Prevention is better than treatment, and the establishment of meticulous oral hygiene and surgical procedures prior to commencing BP treatment is important for preventing BIOJ. Expand
Bisphosphonate-induced necrosis of the jaws: a reconstructive nightmare
TLDR
It is important for the reconstructive head and neck surgeon to recognize the clinical presentation of bisphosphonate-induced osteoradionecrosis of the jaw and the role of conservative management in consistently achieving good results. Expand
Bisphosphonate - related osteonecrosis of the jaws: the point of view of the oral pathologist.
  • G. Ficarra, F. Beninati
  • Medicine
  • Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases
  • 2007
TLDR
The significant benefits that bisphosphonates offer to patients clearly outbalance the risk of potential side effects; however, any patient for whom prolonged bisph phosphonate therapy is indicated, should be provided with preventive dental care in order to minimize therisk of developing this severe condition. Expand
Bisphosphonate-related Osteonecrosis of the Jaws: An Update on Clinical, Pathological and Management Aspects
TLDR
Any patient for whom prolonged bisphosphonate therapy is indicated, should be provided with preventive dental care in order to minimize the risk of developing this severe condition, this article provides an update review of current knowledge about clinical, pathological and management aspects of BRONJ. Expand
Osteonecrosis of the jaw and the role of bisphosphonates: a critical review.
TLDR
Evidence to date suggests that the positive benefits of bisphosphonates in patients with malignant bone disease, osteoporosis, or Paget disease outweigh the relatively small risk of ONJ. Expand
Bisphosphonate – related osteonecrosis of the jaws : the point of view of the oral pathologist Mini-review
Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is mainly reported in patients with bone metastasis from a variety of solid tumors and disseminated multiple myeloma receiving ivExpand
Bisphosphonate - Related Osteonecrosis of the Jaw – Five Years Experience
TLDR
Prevention is the best way to discontinuation of the rising incidence of bisphosphonate related osteonecrosis of the jaw, but it requires a cooperation of interested specialists and also perfect education of the patient. Expand
Effects of Bisphosphonates on the Jaw Bones
Bisphophonates (BPs) are potent inhibitors of bone resorption and are widely used in the treatment of osteoporosis and other diseases that cause loss of bone mass such as Paget’s disease,Expand
Osteonecrosis of Maxilla Secondary to Bisphosphonate Therapy: A Case Report
TLDR
It is indicated that with appropriate technique, primary surgical treatment may offer benefit to selected patients with BR-ONJ and removal of the bone sequestrum with minimal epithelial manipulation associated with topical and systemic antibiotics seem to be the treatment modality of choice. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 78 REFERENCES
Osteonecrosis of the jaw associated with pamidronate therapy
TLDR
The occurrence of osteonecrosis of the jaw associated with pamidronate therapy in 12 patients diagnosed with multiple myeloma, breast carcinomas, or renal cell carcinoma, all involving bone is reported, suggesting that patients should be counseled regarding the possible occurrence of ONJ prior to initiating therapy with pAmidronates. Expand
Bisphosphonate-associated Osteonecrosis of the jaws and endodontic treatment: two case reports.
  • G. Goodell
  • Medicine
  • Journal of the Massachusetts Dental Society
  • 2006
TLDR
Proposed mechanisms of bisphosphonate-associated osteonecrosis of the jaws are reviewed and two case reports where non-surgical and surgical root canal treatment were precipitating factors are described. Expand
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
TLDR
The type of bisphosphonate may play a role and previous dental procedures may be a precipitating factor for this complication and length of exposure seems to be the most important risk factor. Expand
Bisphosphonates and osteonecrosis of the jaw.
TLDR
This volumes seeks to improve awareness of the condition and the need for increased screening and improved diagnosis of ONJ and explores possible treatment options for ONJ to help guide future areas for research. Expand
Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment.
TLDR
Jaw osteonecrosis appears to be associated with the intra-venous use of bisphosphonates, and dental professionals should be aware of this potentially serious complication in periodontal patients receiving long-term treatment with bisph phosphonates. Expand
Bisphosphonate-associated osteonecrosis of the jaws: a review of current knowledge.
TLDR
It is important that clinicians are aware of the association between bisphosphonate treatment and delayed wound healing and osteonecrosis of the jaws and consider referring patients in this population to specialists for even the most routine oral surgery. Expand
Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases.
TLDR
In view of the current trend of increasing and widespread use of chronic bisphosphonate therapy, the observation of an associated risk of osteonecrosis of the jaw should alert practitioners to monitor for this previously unrecognized potential complication. Expand
Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report.
TLDR
Four cases of jawbone necrosis in patients taking pamidronate and zoledronate without having undergone any kind of radiotherapy or dental surgery are reported, suggesting careful evaluation of the patients' oral health before prescribing bisphosphonate treatment. Expand
Osteonecrosis of the maxilla and mandible in patients treated with bisphosphonates: A retrospective study
TLDR
A retrospective chart review of pts with multiple myeloma and metastatic breast cancer who were receiving intravenous BP therapy found 124 pts who presented with exposed bone or ON of the maxilla or mandible and were previously treated with BP were evaluated. Expand
Osteonecrosis of the jaws and bisphosphonates. Report of three cases.
TLDR
Three cases treated in the service of osteonecrosis of the jaws after exodontics are reported, and a treatment based on conservation and as harmless as possible seems to be the most advisable way of acting with patients in order to minimize the incidence and treat the complications. Expand
...
1
2
3
4
5
...